

DOCUMENT NUMBER: 130:61089 ✓  
 TITLE: Treatment of **diabetes** with thiazolidinedione and metformin  
 INVENTOR(S): Smith, Stephen Alistair  
 PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK  
 SOURCE: PCT Int. Appl., 20 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 9857634</u> ✓	A1	19981223	<u>WO 1998-EP3690</u>	19980615 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
<u>AU 9885393</u>	A1	19990104	<u>AU 1998-85393</u>	19980615 <--
<u>EP 996444</u>	A1	20000503	<u>EP 1998-936364</u>	19980615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
<u>BR 9810172</u>	A	20000808	<u>BR 1998-10172</u>	19980615
<u>JP 2002504137</u>	T2	20020205	<u>JP 1999-503755</u>	19980615
<u>NZ 501260</u>	A	20020927	<u>NZ 1998-501260</u>	19980615
<u>CN 1114404</u>	B	20030716	<u>CN 1998-806224</u>	19980615
<u>NZ 515554</u>	A	20030926	<u>NZ 1998-515554</u>	19980615
<u>ZA 9805238</u>	A	20000217	<u>ZA 1998-5238</u>	19980617 <--
<u>NO 9906266</u>	A	19991217	<u>NO 1999-6266</u>	19991217 <--
<u>MX 9912078</u>	A	20000831	<u>MX 1999-12078</u>	19991217
<u>BG 104060</u>	A	20001031	<u>BG 2000-104060</u>	20000106
<u>US 2002004515</u>	A1	20020110	<u>US 2001-925394</u>	20010809
<u>US 2002137772</u>	A1	20020926	<u>US 2002-99161</u>	20020313
<u>CN 1429551</u>	A	20030716	<u>CN 2002-156128</u>	20021206
<u>US 2003109553</u>	A1	20030612	<u>US 2003-340426</u>	20030110
<u>PRIORITY APPLN. INFO.:</u>				
		<u>GB 1997-12857</u>	A	19970618
		<u>GB 1998-6706</u>	A	19980327
		<u>NZ 1998-501260</u>	A1	19980615
		<u>WO 1998-EP3690</u>	W	19980615
		<u>US 1999-446030</u>	B1	19991215
		<u>US 2001-925394</u>	B1	20010809
		<u>US 2002-99161</u>	B1	20020313

AB A method for the treatment and/or prophylaxis of **diabetes mellitus**, conditions assocd. with **diabetes mellitus**, and certain complications thereof, in a mammal which method comprises administering an effective nontoxic and **pharmaceutically** acceptable amt. of an insulin sensitizer rosiglitazone (I) and a biguanide antihyperglycemic agent such as metformin. Pharmacokinetics of I and metformin administered alone or in combination are described. Formulations for prep. tablets contg. I is presented.

IT 155141-29-0, Rosiglitazone maleate

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(treatment of **diabetes** with thiazolidinedione insulin

sensitizer and metformin)  
 RN 155141-29-0 HCAPLUS  
 CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]met  
 hyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 122320-73-4  
 CMF C18 H19 N3 O3 S

PAGE 1-A




PAGE 2-A



CM 2

CRN 110-16-7  
 CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=&gt;